SANNA BASTIANO 1829069 Data last updated 2024-05-11 06:58:14 -0500 US CDT
Latest Holdings
Notice: Data summarized from Form 3,4,5 filings, which do not include holdings/transactions of investment institution(s), if any, managed by the reporter.
Non-derivative Transactions CSV download
Tips: type "code_s" to show transactions with code "S".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-09 | 2023-05-05 | 2023-05-05 to 2023-05-08 | 4 | Sanna Bastiano | EVP, CELL & GENETIC THERAPIES | dsp | 3272.0 | 9.27 | 0.13 | 350.0 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code S | 32038.0
|
257.55 (VRTX) |
| 2023-06-02 | 2023-06-01 | 2023-06-01 | 4 | Sanna Bastiano | DIRECTOR | acq | 5900.0 | 100.0 | 1.37 | 0.0 | Direct | Common Stock | ADICET BIO, INC. | code A | 5900.0 | 42.96 (ACET) |
Derivative Transactions
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-02 | 2023-06-01 | 2023-06-01 | 4 | Sanna Bastiano | DIRECTOR | acq | 26400.0 | 100.0 | 6.15 | 5.2 | Direct | Stock Option (Right To Buy) | ADICET BIO, INC. | code A | 26400.0 | 42.96 (ACET) |
| 2023-08-16 | 2023-08-14 | 2023-08-14 | 4 | Sanna Bastiano | DIRECTOR | dsp | 93400.0 | 100.0 | 21.69 | 10.8 | Direct | Stock Option (Right To Buy) | ADICET BIO, INC. | code D | 0.0
|
43.07 (ACET) |
| 2023-08-16 | 2023-08-14 | 2023-08-14 | 4 | Sanna Bastiano | DIRECTOR | acq | 93400.0 | 100 | 21.69 | 2.14 | Direct | Stock Option (Right To Buy) | ADICET BIO, INC. | code A | 26400.0
|
43.07 (ACET) |
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to records per table for current tier. Access Guide)